Douglass Winthrop Advisors LLC Buys Shares of 3,579 Solventum Co. (NYSE:SOLV)

Douglass Winthrop Advisors LLC purchased a new position in shares of Solventum Co. (NYSE:SOLV) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 3,579 shares of the company’s stock, valued at approximately $250,000.

A number of other large investors also recently modified their holdings of the business. Daiwa Securities Group Inc. raised its position in shares of Solventum by 12.2% during the third quarter. Daiwa Securities Group Inc. now owns 17,623 shares of the company’s stock valued at $1,229,000 after buying an additional 1,919 shares during the last quarter. Centaurus Financial Inc. bought a new position in Solventum during the third quarter valued at about $321,000. Swedbank AB increased its stake in Solventum by 20.3% during the third quarter. Swedbank AB now owns 107,197 shares of the company’s stock valued at $7,474,000 after acquiring an additional 18,108 shares during the period. KKM Financial LLC raised its holdings in Solventum by 7.9% in the 3rd quarter. KKM Financial LLC now owns 4,367 shares of the company’s stock valued at $304,000 after acquiring an additional 319 shares in the last quarter. Finally, Cerity Partners LLC lifted its position in shares of Solventum by 27.4% in the 3rd quarter. Cerity Partners LLC now owns 52,719 shares of the company’s stock worth $3,676,000 after acquiring an additional 11,337 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SOLV shares. Piper Sandler boosted their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research report on Friday, November 8th. Wells Fargo & Company dropped their price objective on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research note on Friday, August 9th. Stifel Nicolaus began coverage on shares of Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock. Morgan Stanley upped their target price on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Finally, The Goldman Sachs Group raised their price target on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research note on Monday, August 12th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $68.00.

Solventum Stock Up 1.1 %

Shares of Solventum stock opened at $71.58 on Tuesday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The firm’s 50-day moving average price is $70.52 and its two-hundred day moving average price is $62.35. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.